Key Takeaways MMSI's $22M C2 CryoBalloon deal broadens GI portfolio, targeting Barrett's esophagus treatment growth.MMSI expects $6-$8M in 2026 revenues from C2 CryoBalloon, despite near-term EPS dilution through 2025-26.MMSI strengthens GI market presence with innovative ablation tech, enhancing long-term growth outlook.Merit Medical Systems (MMSI) announced that it has signed a definitive agreement to acquire the C2 CryoBalloon technology from Pentax of America, a subsidiary of PENTAX Medical, Inc. The in ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, highlighted its recent series of sponsored physician training programs hosted at premier U.S. academic medical centers. Over the past several months, these intensive, hands-on courses at Tulane University and Columbia University have advanced the clinical proficiency o ...